[Determination of antithrombin III in a group workers with long-term exposure to carbon disulfide (CS2)].
Explore the source record for details and available documents.
Adult↗
Biomedical subjects
M Moia
Publications and source records attributed to M Moia.
An improved method for measuring red blood cell filterability.
A new simple method for measuring red blood cell (RBC) filterability by weighing the amount of RBC filtered through micropore membranes is described. Red cell filterability by weighing (RCFW) is determined on washed RBC resuspended in phosphate-buffered saline (PBS) at low (5%) hematocrit. The filtration step is performed using gravity alone and the amount of the filtered suspension is referred to the filtration of PBS alone through the same membrane. The new method shows a reproducibility better than that of the widely used Dormandy technique, with a lower coefficient of variation (5.3 vs. 7.2%) and a higher sensitivity to artificially hardened RBC.
Blood Viscosity↗
Venous thrombosis from air travel: the LONFLIT3 study--prevention with aspirin vs low-molecular-weight heparin (LMWH) in high-risk subjects: a randomized trial.
The LONFLIT1 and 2 studies established that in high-risk subjects after long (>10 hours) flights, the incidence of deep venous thrombosis (DVT) may be between 4% and 6%, The LONFLIT3 study aimed to evaluate methods of prevention in high-risk subjects. Of 467 subjects contacted for the study, 300 were included. These 300 subjects at high risk for DVT were randomized, after informed consent, into three groups: 1) a control group that had no prophylaxis; 2) an aspirin treatment group, in which patients were treated with 400 mg (tablets of oral, soluble aspirin; one dose daily for 3 days, starting 12 hours before the beginning of the flight); and 3) a low-molecular-weight heparin (LMWH) group, in which one dose of enoxaparine was injected between 2 and 4 hours before the flight. The dose was weight-adjusted (1,000 IU [equivalent to 0.1 mL per 10 kg of body weight). Subjects with potential problems due to prophylaxis with aspirin or LMWH or at risk of drug interactions were excluded. Of the 100 included subjects in each group, a total of 249 subjects completed the study (dropouts due to low compliance or traveling/connections problems were 17%). Age and sex distribution were comparable in the three groups as well as risk distributions. Mean age was 47 (range, 28-75; SD, 11; 65% males). Of the 82 subjects in the control group, there were 4.82% of subjects with DVT with two superficial thromboses. In total 4.8% of limbs suffered a thrombotic event. Of 84 subjects in the aspirin treatment group, there were 3.6% of patients with DVT and three superficial thrombosis. In total 3.6% of limbs had a thrombotic event. In the LMWH group (82 subjects), there were no cases of DVT. One superficial thrombosis was documented. In total only 0.6% of limbs had a thrombotic event (p<0.002 in comparison with the other two groups). DVT was asymptomatic in 60% of subjects; 85% of DVTs were observed in passengers in non-aisle seats. Mild gastrointestinal symptoms were reported in 13% of patients taking aspirin. One dose of LMWH is an important option to consider in high-risk subjects during long-haul flights.
Adult↗
[Arg506 --> Gln mutation of coagulation factor V (factor V Leiden) and transient cerebral ischemia at a young age in 3 members of the same family].
The Arg506 --> Gln coagulation factor V mutation (factor V Leiden) is the most frequent inherited abnormality of blood coagulation which predisposes to venous thromboembolism. Its association with an increased risk of arterial thrombosis is uncertain. We describe 3 members of the same family (a woman and her 2 children) who were heterozygous for the Arg506 --> Gln mutation and who presented cerebral transient ischemic attacks (TIA) at a young age. The patients (with the exception of one smoker) had no risk factors for TIA and no abnormality of the coagulation system other than the Arg506 --> Gln mutation. The observation of the mutation and TIA in 3 members of the same family may suggest the hypothesis of an association between the mutation and arterial thrombosis. This hypothesis must be interpreted with caution, due to the absence of objective instrumental findings in patients with TIA and to the high prevalence of the Arg506 --> Gln mutation in the general population.
Adult↗
Rationale for the use of a low molecular weight heparin during hemodialysis with polysulphone membrane in uremic patients.
We carried out an open, randomized, cross-over study to test the rationale for use of a low molecular weight heparin during hemodialysis with polysulphone membranes. Ten uremic patients (6 men, 4 women, mean age 50 +/- 11 years, range 31-70) in chronic hemodialysis underwent paired filtration dialysis with either low molecular weight heparin or unfractionated heparin, then crossed over to the other anticoagulant treatment. We measured the following: anti-factor Xa and anti-factor IIa activity in patients' plasma and in the ultrafiltrate, activated partial thromboplastin time and bleeding time before, during and after hemodialysis. Some low molecular weight fractions of heparin were lost in the ultrafiltrate during hemodialysis, while higher molecular weight fractions were retained. The activated partial thromboplastin time during dialysis and the bleeding time after dialysis were more prolonged with unfractionated heparin than with the low molecular weight heparin (p < 0.01 and p < 0.05 respectively). Our data indicate that the use of a low molecular weight heparin determines a less pronounced prolongation of the activated partial thromboplastin time during dialysis and prevents a post-dialytic increase in bleeding time.
Adult↗
Venous thromboembolism after laparoscopic surgery: two case reports and review of the literature.
Two cases of deep vein thrombosis and pulmonary embolism in patients who had undergone laparoscopic surgery (cholecystectomy and inguinal hernioplasty in the first and crural hernioplasty in the second) are described. These cases suggest that prophylaxis for venous thromboembolism should also be given to patients who undergo relatively noninvasive surgery such as laparoscopic intervention. The presentation concludes with a review of the last 7 years' literature on this topic.
Aged↗